BRPI0606360A2 - método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas - Google Patents

método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas

Info

Publication number
BRPI0606360A2
BRPI0606360A2 BRPI0606360-8A BRPI0606360A BRPI0606360A2 BR PI0606360 A2 BRPI0606360 A2 BR PI0606360A2 BR PI0606360 A BRPI0606360 A BR PI0606360A BR PI0606360 A2 BRPI0606360 A2 BR PI0606360A2
Authority
BR
Brazil
Prior art keywords
treating
cancer cells
proliferative disorder
apoptosis
death receptor
Prior art date
Application number
BRPI0606360-8A
Other languages
English (en)
Inventor
Avi J Ashkenazi
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0606360A2 publication Critical patent/BRPI0606360A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODO PARA MELHORAR A APOPTOSE, MéTODO PARA TRATAR UMA DESORDEM PROLIFERATIVA E MéTODO PARA TRATAR CéLULAS CANCEROSAS. São fornecidos métodos de uso dos ligantes de receptor de morte, tais como polipeptídeos de Apo-2 ligante/TRAIL ou anticorpos para receptor de morte, e inibidores de EGFR para tratar condições patológicas como, por exemplo, o câncer. As incorporações da invenção incluem métodos de uso da Apo2LITRAIL ou anticorpos para receptor de morte, tais como anticorpos DR5 e DR4, combinados com inibidores de EGFR, como Tarceva
BRPI0606360-8A 2005-02-18 2006-02-16 método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas BRPI0606360A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/061,258 US20060188498A1 (en) 2005-02-18 2005-02-18 Methods of using death receptor agonists and EGFR inhibitors
PCT/US2006/005459 WO2006089015A2 (en) 2005-02-18 2006-02-16 Methods of using death receptor agonists and egfr inhibitors

Publications (1)

Publication Number Publication Date
BRPI0606360A2 true BRPI0606360A2 (pt) 2009-06-23

Family

ID=36912953

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606360-8A BRPI0606360A2 (pt) 2005-02-18 2006-02-16 método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas

Country Status (13)

Country Link
US (1) US20060188498A1 (pt)
EP (1) EP1853300B1 (pt)
JP (2) JP2008532937A (pt)
KR (1) KR20070110852A (pt)
CN (1) CN101180072A (pt)
AU (1) AU2006214292A1 (pt)
BR (1) BRPI0606360A2 (pt)
CA (1) CA2595931A1 (pt)
IL (1) IL184827A0 (pt)
NO (1) NO20074740L (pt)
RU (1) RU2429006C2 (pt)
WO (1) WO2006089015A2 (pt)
ZA (1) ZA200706859B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530588A (ja) * 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
CA2778435A1 (en) * 2008-11-06 2010-05-14 Wayne State University Vaccines targeting cellular death receptors
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc DR5 Ligand-HEILMITTELKONJUGATE
US20130064838A1 (en) * 2010-05-14 2013-03-14 Amgen Inc. Enhanced death receptor agonists
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
ITPD20110091A1 (it) * 2011-03-24 2012-09-25 Univ Padova Inibitori multitirosinchinasi utili per le patologie correlate: modelli farmacoforici, composti identificati tramite questi modelli, metodi per la loro preparazione, la loro formulazione e il loro impiego terapeutico.
MX2013012716A (es) * 2011-05-03 2014-03-21 Genentech Inc Agentes de disociacion vascular y sus usos.
CN102675225A (zh) * 2012-05-16 2012-09-19 浙江理工大学 一种盐酸埃罗替尼的合成方法
RU2580220C2 (ru) * 2012-11-07 2016-04-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) РЕКОМБИНАНТНАЯ ПЛАЗМИДА рСрG-СytDA/upp ДЛЯ ЭКСПРЕССИ ГИБРИДНОГО БЕЛКА ЦИТОЗИНДЕЗАМИНАЗА-УРАЦИЛФОСФОРИБОЗИЛ ТРАНСФЕРАЗА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА рСрG-СytDA/upp/VP22 ДЛЯ ЭКСПРЕССИИ ГИБРИДНОГО БЕЛКА ЦИТОЗИНДЕЗАМИНАЗА-УРАЦИЛФОСФОРИБОЗИЛ ТРАНСФЕРЕЗА-VP22, ЛЕЧЕБНАЯ КОМПОЗИЦИЯ ДЛЯ ТЕРАПИИ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ И СПОСОБ ЕЕ ПРИМЕНЕНИЯ
US9556203B2 (en) * 2013-10-04 2017-01-31 Piqur Therapeutics Ag Conformationally restricted P13K and mTOR inhibitors
CN103833853B (zh) * 2013-12-25 2019-05-17 河南大学 新型死亡受体激动性多价抗体及其在制备抗肿瘤药物中的应用
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
JP6629753B2 (ja) * 2014-04-03 2020-01-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がん治療剤の組合せ
NO2776305T3 (pt) * 2014-04-23 2018-01-27
EP3229806A1 (en) 2014-12-12 2017-10-18 Merck Patent GmbH Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
CN105801495A (zh) * 2014-12-31 2016-07-27 徐州万邦金桥制药有限公司 一种盐酸厄洛替尼合成纯化方法
DK3389696T3 (da) 2015-12-17 2024-12-16 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
JP7197370B2 (ja) * 2016-06-17 2022-12-27 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア がんの予防および／または治療のための化合物、組成物および方法
WO2019154230A1 (zh) * 2018-02-08 2019-08-15 四川大学华西医院 一种包含TRAIL和IgG结合结构域的融合蛋白及其用途
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN119371319A (zh) * 2024-10-25 2025-01-28 安徽尖峰北卡药业有限公司 一种用于埃罗替尼中间体生产工艺及其生产系统

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2230492C (en) 1995-09-21 2009-05-26 Genentech, Inc. Human growth hormone variants
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) * 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
ATE227283T1 (de) * 1996-07-13 2002-11-15 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
US7452538B2 (en) * 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
ATE516354T1 (de) 1997-05-15 2011-07-15 Genentech Inc Apo-2-rezeptor
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
JP3687900B2 (ja) * 1998-11-19 2005-08-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー チロシンキナーゼの不可逆的阻害剤であるｎ−［４−（３−クロロ−４−フルオロフェニルアミノ）−７−（３−モルホリン−４−イルプロポキシ）キナゾリン−６−イル］アクリルアミド
JP2005508162A (ja) * 2001-10-02 2005-03-31 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド変異体とその使用法
DK1450847T3 (da) * 2001-11-13 2010-12-13 Genentech Inc Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
RU2240125C2 (ru) * 2002-11-12 2004-11-20 Государственное учреждение Гематологический научный центр РАМН СПОСОБ ЭФФЕКТИВНОЙ ИНДУКЦИИ АПОПТОЗА В СУСПЕНЗИОННЫХ КУЛЬТУРАХ ОПУХОЛЕВЫХ PH$$$ КЛЕТОК КОСТНОГО МОЗГА И ПЕРИФЕРИЧЕСКОЙ КРОВИ БОЛЬНЫХ Ph+ ЛЕЙКОЗАМИ С ПОМОЩЬЮ АНТИСЕНС ОЛИГОНУКЛЕОТИДОВ, СПЕЦИФИЧНЫХ К МРНК ГЕНОВ, ИНГИБИРУЮЩИХ АПОПТОЗ
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
PL1622929T3 (pl) * 2003-05-09 2007-03-30 Genentech Inc Peptydy wiążące się z receptorem APO2L(TRAIL) oraz ich zastosowanie

Also Published As

Publication number Publication date
JP2012229237A (ja) 2012-11-22
CA2595931A1 (en) 2006-08-24
WO2006089015A3 (en) 2007-08-23
EP1853300A2 (en) 2007-11-14
AU2006214292A1 (en) 2006-08-24
EP1853300B1 (en) 2014-07-23
KR20070110852A (ko) 2007-11-20
IL184827A0 (en) 2008-08-07
CN101180072A (zh) 2008-05-14
JP2008532937A (ja) 2008-08-21
WO2006089015A2 (en) 2006-08-24
NO20074740L (no) 2007-11-14
RU2007134568A (ru) 2009-03-27
RU2429006C2 (ru) 2011-09-20
US20060188498A1 (en) 2006-08-24
ZA200706859B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
BRPI0606360A2 (pt) método para melhorar a apoptose, método para tratar uma desordem proliferativa e método para tratar células cancerosas
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
MX2007006640A (es) Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
WO2007149427A3 (en) Tyrosine kinase inhibitors
UA116187C2 (uk) ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
GEP20125517B (en) Humanized monoclonical antibodies to hepatocyte growth factor
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
BR112012011529A2 (pt) sistema de laser, e, método para escanear um feixe de laser
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
BR112012011528A2 (pt) métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
WO2010056309A3 (en) Methods and compositions related to targeting monoacylglycerol lipase
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
EA201190025A1 (ru) ПРИМЕНЕНИЕ АНТАГОНИСТОВ DR6 И p75 ДЛЯ ПРОМОТИРОВАНИЯ ВЫЖИВАНИЯ КЛЕТОК НЕРВНОЙ СИСТЕМЫ
EA200970738A1 (ru) Ингибиторы активности akt
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
BRPI0821151A2 (pt) Derivados de pirazol e uso dos mesmos como inibidores de quinases dependentes de ciclina
EA200801732A1 (ru) Модуляторы ауроракиназы, способы их получения и их применение
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA200901249A1 (ru) Ингибиторы связывания протеинкиназ
BRPI0515604A (pt) método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL